Vertaling van "provision " (Nederlands → Frans) :

The provision of scientific advice at the level of the EMEA has been a particular success in recent years.
The provision of scientific advice at the level of the EMEA has been a particular success in recent years.

Provision has been made for the organised exchange of information with the national scientific commissions which give final opinions (e.g. evaluation commissions for medicines) and with the representatives on the international scientific or regulatory committees (e.g. CHMP, CVMP, CMD(h), CMD(v), COMP, PDCO).
Provision has been made for the organised exchange of information with the national scientific commissions which give final opinions (e.g. evaluation commissions for medicines) and with the representatives on the international scientific or regulatory committees (e.g. CHMP, CVMP, CMD(h), CMD(v), COMP, PDCO).

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Depreciation, amortization and impairments 1 712 2 119 –407 Change in provisions and other non-current liabilities 436 420 16 Net financial expense/income 301 –112 413 Other 248 –2 250 Net income adjusted for non-cash items 9 927 10 165 –238 Interest and other financial receipts 590 608 –18 Interest and other financial payments –498 –585 87 Taxes paid –1 217 –1 570 353 Cash flow before working capital changes 8 802 8 618 184 Payments out of provisions and other net cash movements in non-current liabilities –567 –481 –86
Dépréciations, amortissements et pertes de valeur 1 712 2 119 –407 Variation des provisions et autres passifs non courants 436 420 16 Charges/produits financiers nets 301 –112 413 Autres 248 –2 250 Résultat net ajusté des éléments non monétaires 9 927 10 165 –238 Intérêts encaissés et autres produits financiers 590 608 –18 Intérêts payés et autres charges financières –498 –585 87 Impôts payés –1 217 –1 570 353 Flux de trésorerie avant variation du fonds de roulement 8 802 8 618 184 Paiements en espèces prélevés sur les provisions et autres mouvements en espèces nets des passifs non courants –567 –481 –86

Depreciation, amortization and impairments 1 237 614 623 Change in provisions and other non-current liabilities -51 201 -252 Net financial expense 161 122 39 Other -246 141 -387 Net income adjusted for non-cash items 3 895 3 569 326 Interest and other financial receipts -230 20 -250 Interest and other financial payments -173 -363 190 Taxes paid -638 -289 -349 Cash flow before working capital changes 2 854 2 937 -83 Payments out of provisions and other net cash movements in non-current liabilities -311 -145 -166
Dépréciation, amortissements et pertes de valeur 1 237 614 623 Variation des provisions et autres passifs non courants -51 201 -252 Charges financières nettes 161 122 39 Autres -246 141 -387 Résultat net ajusté des éléments non monétaires 3 895 3 569 326 Intérêts et autres produits financiers encaissés -230 20 -250 Intérêts et autres charges financières payés -173 -363 190 Impôts payés -638 -289 -349 Flux de trésorerie avant variation du fonds de roulement 2 854 2 937 -83 Charges de restructuration et autres paiements en numéraire prélevés sur les provisions -311 -145 -166

Depreciation, amortization and impairments 614 861 –247 Change in provisions and other non-current liabilities 201 203 –2 Net financial expense/income 122 3 119 Other 141 82 59 Net income adjusted for non-cash items 3 569 3 569 0 Interest and other financial receipts 20 37 –17 Interest and other financial payments –363 26 –389 Taxes paid –289 –394 105 Cash flow before working capital changes 2 937 3 238 –301 Payments out of provisions and other net cash movements in non-current liabilities –145 –174 29
Dépréciation, amortissements et pertes de valeur 614 861 –247 Variation des provisions et autres passifs non courants 201 203 –2 Charges/produits financiers nets 122 3 119 Autres 141 82 59 Résultat net ajusté des éléments non monétaires 3 569 3 569 0 Intérêts encaissés et autres produits financiers 20 37 –17 Intérêts payés et autres charges financières –363 26 –389 Impôts payés –289 –394 105 Flux de trésorerie avant variation du fonds de roulement 2 937 3 238 –301 Paiements en espèces prélevés sur les provisions et autres mouvements en espèces nets des passifs non courants –145 –174 29

The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.
The latter involves, on the one hand, the provision of relevant information about authorised medicines and health products aimed at the different target groups, and, on the other hand, the partnership with bodies responsible for the distribution of independent information, such as the BCFI - CBIP.

In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.
In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.

Another significant activity is the provision of national scientific and technical regulatory advice.
Another significant activity is the provision of national scientific and technical regulatory advice.